Eric Benjamin Sells 12,394 Shares of Insulet Co. (NASDAQ:PODD) Stock

Insulet Co. (NASDAQ:PODD) EVP Eric Benjamin sold 12,394 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the transaction, the executive vice president now owns 11,383 shares in the company, valued at $3,187,240. The trade was a 52.13 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Insulet Price Performance

Insulet stock opened at $277.20 on Friday. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The company has a market capitalization of $19.44 billion, a PE ratio of 47.47, a P/E/G ratio of 3.47 and a beta of 1.22. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $282.86. The stock has a 50-day moving average price of $266.84 and a two-hundred day moving average price of $234.68.

Insulet (NASDAQ:PODD) last posted its earnings results on Thursday, November 7th. The medical instruments supplier reported $0.90 EPS for the quarter, beating the consensus estimate of $0.77 by $0.13. The firm had revenue of $543.90 million during the quarter, compared to the consensus estimate of $518.50 million. Insulet had a return on equity of 27.98% and a net margin of 21.22%. During the same period last year, the company earned $0.71 earnings per share. Analysts expect that Insulet Co. will post 3.22 EPS for the current year.

Hedge Funds Weigh In On Insulet

Several large investors have recently bought and sold shares of PODD. Envestnet Asset Management Inc. raised its position in Insulet by 4.9% in the second quarter. Envestnet Asset Management Inc. now owns 87,718 shares of the medical instruments supplier’s stock valued at $17,702,000 after purchasing an additional 4,065 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Insulet by 10.0% during the second quarter. Dimensional Fund Advisors LP now owns 146,746 shares of the medical instruments supplier’s stock worth $29,618,000 after acquiring an additional 13,351 shares during the last quarter. Mercer Global Advisors Inc. ADV bought a new position in shares of Insulet during the second quarter worth about $158,000. Beck Bode LLC raised its position in shares of Insulet by 33.6% during the second quarter. Beck Bode LLC now owns 93,187 shares of the medical instruments supplier’s stock worth $18,805,000 after acquiring an additional 23,426 shares during the last quarter. Finally, Pacer Advisors Inc. raised its position in shares of Insulet by 36.3% during the second quarter. Pacer Advisors Inc. now owns 6,506 shares of the medical instruments supplier’s stock worth $1,313,000 after acquiring an additional 1,734 shares during the last quarter.

Analyst Ratings Changes

PODD has been the topic of several analyst reports. Citigroup increased their target price on Insulet from $283.00 to $310.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Morgan Stanley increased their target price on Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a report on Monday, November 11th. Canaccord Genuity Group increased their target price on Insulet from $269.00 to $304.00 and gave the stock a “buy” rating in a report on Monday, December 9th. Sanford C. Bernstein initiated coverage on Insulet in a report on Wednesday, November 6th. They set an “outperform” rating and a $300.00 target price on the stock. Finally, Barclays increased their target price on Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. Three research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $272.81.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.